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  Cost-utility analysis (CUA) studies are becoming increasingly 
important due to the need to reduce healthcare spending, 
especially in the field of trauma and orthopaedics.
  There is an increasing need for trauma and orthopaedic 
surgeons to understand these economic evaluations to 
ensure informed cost-effective decisions can be made to 
benefit the patient and funding body.
  This review discusses the fundamental principles required 
to understand CUA studies in the literature, including a 
discussion of the different methods employed to assess 
the health outcomes associated with different manage-
ment options and the various approaches used to calcu-
late the costs involved.
  Different types of model design may be used to conduct 
a CUA which can be broadly categorized into real-life 
clinical studies and computer-simulated modelling. We 
discuss the main types of study designs used within each 
category. We also cover the different types of sensitivity 
analysis used to quantify uncertainty in these studies and 
the commonly employed instruments used to assess the 
quality of CUAs. Finally, we discuss some of the important 
limitations of CUAs that need to be considered.
  This review outlines the main concepts required to under-
stand the CUA literature and provides a basic framework 
for their future conduct.
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Introduction
With any musculoskeletal disease or injury, there are dif-
ferent potential management options available that have 
varying costs and benefits to the patient. A judgement can 
be made as to which management option is the more cost-
effective option compared to the others. This is usually 
achieved via calculating and then comparing the added 
health outcomes and associated costs over a specific time 
frame between two particular management options for 
a given condition. For example, one may consider which 
of resurfacing or non-resurfacing the patella in total knee 
arthroplasty (TKA) is the more cost-effective over a given 
duration. In trauma and orthopaedics, cost-effectiveness 
is becoming increasingly important due to rising health-
care spending, especially due to the ageing population, in 
the presence of many possible management options and 
a resource-limited environment.
A special case of cost-effectiveness analysis (CEA), the 
cost-utility analysis (CUA), is discussed in this review. A CUA 
is an economic analysis that compares the relative costs 
and health outcomes in quality-adjusted life-years (QALYs) 
of different management options and enables a judge-
ment as to the more cost-effective option. Their aim is to 
minimize costs for the greatest possible justified increase in 
patient-reported health outcomes. The importance of cost-
effectiveness analyses was initially emphasized to guide 
public health policies in developing countries. These CEAs 
were motivated partly by the belief that countries could 
achieve better health outcomes in quantity and quality 
simply by redirecting the limited resources available. In 
1996, the First Panel on Cost-Effectiveness in Health and 
Medicine outlined the first consensus-based guidelines 
for the conduct of CEAs to improve the comparability and 
quality of these studies.1 Therefore, CUAs offer important 
information that may guide decision-making by institu-
tions in developing the most cost-effective clinical guide-
lines and practices.
However, in order to understand these studies, knowl-
edge about several key areas is required. This includes an 
understanding of the methods used to quantify health 
outcomes and costs associated with a particular manage-
ment option, the different CUA model types, the sensitivity 
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analyses used, and the methods employed for evaluating 
study quality. Below, we discuss these five areas as well as 
the limitations of CUAs.
Measuring health utility and incremental 
cost-utility ratio
In CUAs, healthcare outcomes are quantified using quality- 
adjusted life-years (QALYs). This value is a subjective self-
reported measure of the perceived quality of life expe-
rienced by the patient over a given period of time. It is 
calculated by the utility (measure of worth or value in 
economics) of a given health state multiplied by the years 
lived in that state.2 Thus, one QALY is equal to one year of 
perfect health. First, the QALY values following a manage-
ment option and its comparator must be determined for 
a particular condition over a specific time frame. An incre-
mental cost-utility ratio (ICUR) must then be calculated 
by dividing the difference in total costs between the two 
management options over the same specific time frame 
by the difference in the aforementioned reported QALYs 
for each. Thus, the ICUR gives the cost per additional 
QALY gained as a result of the management option over 
its comparator.3 It should be noted that many studies use 
the terms ICUR and ICER (incremental cost-effectiveness 
ratio) interchangeably.
The ICUR is then compared to the willingness-to-pay 
(WTP) threshold. In the European Union, the decision-
makers’ WTP is defined as the maximum a healthcare con-
sumer is willing to pay per additional QALY gained by the 
more expensive management option. Furthermore, it is 
important to acknowledge that most countries do not set 
a threshold, and even in the few that do, it is not used as 
the sole criterion for decision-making. Other criteria may 
include the impact on budget, uncertainty around model 
estimates and the degree of unmet medical need. There is 
also significant variability in the thresholds set by the dif-
ferent countries that employ WTP thresholds, which may 
perhaps be attributed to the methodological differences 
used to establish them.4
Only the National Institute for Health and Care Excel-
lence (NICE) in England and Wales explicitly uses a fixed 
threshold as its WTP, which is kept between £20,000 and 
£30,000.5 In contrast, other countries use specific figur-
ers or ranges as recommendations but have not formally 
adopted them. The commonly quoted WTPs for some 
of these countries are shown for comparison in Table 1 
below. If the ICUR is below the WTP threshold, the man-
agement option is considered cost-effective relative to the 
comparator over the given time frame. Therefore, ICURs 
offer a valuable metric that may help inform policy-making 
in healthcare governing bodies.
The methods used to measure health utility values can 
be either direct or indirect.
Direct measures of health utility
In time trade off (TTO), the patients choose between 
remaining in a given state of ill health for a given period 
of time or being restored to perfect health but trading 
in years off their life, e.g. living 10 years in a health state 
with severe knee pain or trading years off your life to live 
a shorter period in perfect health. If five of the 10 years are 
willing to be traded, then the knee pain health state has 
a utility value of 0.5. Rubén Mota used TTO in a Markov 
model to assess the cost-effectiveness of early primary 
total hip replacement (THR) for older adult patients with 
osteoarthritis against either non-surgical therapy followed 
by THR once the patient had progressed to a functionally 
dependent state, or non-surgical therapy alone from the 
Italian national health system perspective.11
In Standard Gamble, the patient is asked to choose 
between two options. The first is a certain option whereby 
the person remains in a given health state A for ‘X’ years. 
The second is a gamble, an option with an element of 
risk whereby the person may either be returned to full 
health for the remaining ‘X’ years (with probability p) or 
dies immediately (with probability 1-p). The probability of 
death is altered until the respondent is indifferent to the 
two available options (point of indifference). If this point 
of indifference is found when the probability of death is, 
for example 80%, this would suggest that the individual 
values health state A to be 80% of full health.12 This means 
the utility of health state A would be 0.8. Marsh et al used 
Standard Gamble to measure health utility for the calcu-
lation of the QALY in patients who received both arthro-
scopic debridement of degenerative articular cartilage 
and resection of degenerative meniscal tears in addition to 
non-operative management for knee osteoarthritis and in 
patients who received non-operative management only.13
The visual analogue scale (VAS) method offers the sim-
plest and most subjective measure of health utility. Here 
the patient rates their own state of health, often in terms 
of pain, on a scale of 0 (no pain) to 100 (severe pain).14 
Wang et al sought to evaluate the cost-utility of percuta-
neous endoscopic transforaminal discectomy (PETD) and 
percutaneous endoscopic interlaminar discectomy (PEID) 
for the treatment of L5-S1 lumbar disc herniation in a CUA 
using VAS.15
Table 1. Examples of the ICUR thresholds used by CUA studies in various 
countries






Notes. ICUR, incremental cost-utility ratio; CUA, cost-utility analysis; QALY, 
quality-adjusted life-years.
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Indirect measures of health utility
The EQ-5D is a questionnaire designed by the EuroQol group 
for self-completion by the patient as an indirect measure of 
healthcare utility using a scoring system for each response.16 
In this version, five dimensions are used as measures includ-
ing mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. The patients rate their degree of severity 
for each dimension using either the three-level (EQ-5D-3L) 
or five-level (EQ-5D-5L) scale. Following an additional EQ-
VAS, the score from this section is then converted into a 
preference weight as a measure of health utility.16
The Short Form-36 (SF-36) Health Survey is a 36-item 
questionnaire of healthcare utility designed for self-
completion by the patient.17 The SF-36 measures eight 
scales: vitality, physical functioning, bodily pain, general 
health, physical role functioning, emotional role function-
ing, social role functioning and mental health. It has been 
shown through component analysis that two distinct con-
cepts are measured: a physical dimension and a mental 
dimension, represented by the physical component sum-
mary (PCS) and mental component summary (MCS), 
respectively.17 Each of the component scales contribute in 
different proportions to the calculation of these two sum-
mary measures. They offer valuable insight into a patient’s 
current health state. However, it is worth noting that 
although many researchers continue to use and to extrap-
olate from these measures an overall single health utility, 
this is not supported by the SF-36 scoring manual.18 In 
osteoarthritis studies, the SF-36 is often combined with 
the Western Ontario and McMaster’s Universities Osteo-
arthritis Index (WOMAC), or the Lequesne index, which 
measure function and pain.19,20
Developed in 2005, the Osteoarthritis Knee and Hip 
Quality of Life questionnaire (OAKHQOL) was the first 
questionnaire developed to measure quality of life in 
patients specifically with knee and hip osteoarthritis.21 This 
instrument consists of 43 items in five dimensions (physi-
cal activity, mental health, social functioning, social sup-
port and pain) and three independent items. Each item is 
measured using a numerical self-reported rating from 0 to 
10. If the individual fails to answer at least half the items 
for a particular dimension, the score for that dimension 
is dropped. Raw scores are obtained by first computing 
the mean of the item scores for each dimension. These 
are then normalized to a scale from 0 (worst) to 100 (best 
possible health utility). This instrument has been shown to 
cover the highest number of osteoarthritis core set catego-
ries and capture specific aspects that are very important 
for knee and hip osteoarthritis patients.22 These core set 
categories refer to the International Classification of Func-
tioning, Disability and Health (ICF) core sets, which are 
short lists of ICF categories developed by experts that are 
important for patients with a specific disease. The ICF core 
set for osteoarthritis contains 55 categories.23
Perspective used for calculating costs
The healthcare costs incurred in the management of medi-
cal conditions used in ICUR calculations can be considered 
from either the direct (healthcare) or indirect (societal) 
perspective. The direct costs comprise healthcare costs 
such as the primary and subsequent treatments, medi-
cation and hospital bed space.24 In contrast, the indirect 
costs take into account the societal costs incurred as a 
result of the management option such as loss of produc-
tivity, absenteeism and informal healthcare costs.25
The choice of the perspective used is dependent on 
the decision problem (e.g. an investment decision for 
a hospital or to inform a reimbursement request to the 
government). However, the European Network for Health 
Technology Assessment (EUnetHTA) recommends that all 
economic evaluations to be conducted from a healthcare 
perspective at a minimum. However, several countries 
recommend a societal perspective including Norway, 
Denmark, and Sweden.26
Weeks et al evaluated only the direct healthcare costs 
when comparing the cost-utility of patellar resurfacing in 
TKA and non-resurfacing.24 The costs were obtained from 
the finance department at the Schulich School of Medi-
cine and Dentistry in Ontario, Canada. The procedure 
costs included the cost of the equipment, implant, thea-
tres, time spent in theatres, length of stay in the hospital 
and the various medical and laboratory tests during the 
initial hospitalization period.
Buvik et al evaluated the cost-utility of telemedicine in 
remote orthopaedic consultations from the societal per-
spective.27 Three types of costs were included: the costs 
of implementing and running the telemedicine service 
in clinical practice (e.g. screen and camera at the remote 
centre and hospital for videoconferencing), travel costs 
of the patient to the remote centre (considering time, 
distance and mode of transport) and production losses 
due to patients having to take time off work to attend the 
orthopaedic consultation.
In order to improve the accuracy of these calculated 
costs, they must be first corrected via inflation adjustment 
and discounting. These are outlined below.
Inflation adjustment
Healthcare costs are measured in various currencies 
depending on the country of origin of the data and may 
be accrued over many different years. This is important 
because, for example, in the UK, the value of a pound in 
one year may not hold the same value in another due to 
inflation or deflation. Thus, inflation adjustment must be 
carried out for these costs. The general recommendations 
would be to express the costs in values of the current (or 
most recent) year and that if older values are used, these 
should be adjusted for inflation using the appropriate 
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price index figure. There are several indices that could be 
used. For European countries, indices of consumer prices 
may be found on the Eurostat webpage.28 Unadjusted 
values are ‘nominal’, whilst those that are adjusted are 
considered ‘real’. Conversion into ‘real’ values allows the 
comparison of costs incurred in different years within and 
between studies and is important for ICUR calculations.29
Discounting
Another important consideration when calculating both 
costs and health outcomes of healthcare management 
options whose benefit materializes in the future is the 
use of discounting.30 This is the adjustment of both costs 
and health outcomes to the ‘present value’ for the time 
at which they occur. Discounting is essential because 
people generally value future costs and health outcomes 
less than current costs and health outcomes. Thus, their 
values diminish the more distantly in the future that they 
occur. To perform this adjustment, the value of the costs 
or health outcome measures (e.g. QALY), for each year in 
the future (n), is multiplied by (1/(1 + discount rate)n).31 
Hence, greater discount rates or longer delays between 
treatment and benefit precipitate lower net present val-
ues for both costs and health outcomes. For example, 
discounting may be significant in the case of autologous 
chondrocyte implantation (ACI) to treat isolated full-thick-
ness articular cartilage defects of the knee (upfront costs 
and delayed health benefits) or negligible in intra-articular 
steroid injections (where costs and benefits occur upfront 
simultaneously).
The discount rates stated in the national guidelines for 
economic evaluations should be applied. The EUnetHTA 
recommends the use of a discount rate between 3% and 
5% for both costs and effects, as do most recommenda-
tions in European guidelines.26 It is recommended that 
both costs and effects are discounted in the base case 
analysis with the same rate. It is also recommended that 
sensitivity analyses which explore the effect of varying the 
discount rate and the use of differential discount rates 
(e.g. a lower discount rate for benefits than costs) should 
be incorporated into the CUA.
Time horizon length
The time horizon length refers to the duration over which 
health outcomes (e.g. QALYs) and costs are measured 
and calculated. The same time horizon length should be 
used for both. An appropriate time horizon depends on 
the nature of the disease, the management option under 
consideration and the purpose of the analysis. As recom-
mended by the EUnetHTA, it should be long enough to 
reflect all the important differences in costs and health 
outcomes between the management options being com-
pared in the CUA.26 Importantly, guidelines from certain 
countries (e.g. those from the UK, Finland, Ireland, Nor-
way and Spain) explicitly state that this may mean a life-
time if the management option leads to differences in 
health utility that persist for the remainder of a patient’s 
life. This may require extrapolation of available data, 
which is certainly relevant to many orthopaedic surgery 
procedures.32
Different types of CUA model design
Different CUA model designs may be used to calculate 
the different costs and utility values of different manage-
ment options over a given time horizon. These may be 
divided into either real-life clinical studies or computer 
simulations. According to the EU guidelines, the decision 
on whether to use a real-life clinical trial or a computer- 
simulation model depends on the research question. 
Model-based studies should be used when the manage-
ment option effects are expected in the long term, when 
the incidence of the clinical endpoint is low or when it 
is not possible for all relevant alternative management 
options to be included in one study. A trial-based study 
is appropriate in other cases.33 The most commonly used 
real-life clinical study types are randomized controlled 
studies and prospective cohort studies.
Randomized controlled trials
Randomized controlled trials are considered to be the 
gold standard of scientific research. They are longitudi-
nal studies whereby a number of people are randomly 
assigned to two or more groups to test the effect of a 
particular management option. Each group will have dif-
ferent management options being tested on them. The 
outcome measures (i.e. costs and health utility values) 
are measured at specific times within the particular time 
frame being used. The aforementioned study by Buvik et 
al evaluated the cost-utility of remote telemedicine ortho-
paedic consultations compared to standard outpatient 
consultations at a hospital via a randomized controlled 
trial of 389 patients from 2007 to 2012.27
Prospective cohort studies
Prospective cohort studies are similar to randomized con-
trol studies. However, the individuals assigned to each 
study group are not randomly selected but have a par-
ticular factor (e.g. treatment via a particular management 
option) in common, whose impact on health outcomes 
and costs is under study. Therefore, this type of study 
allows the impact of, in the case of CUAs, the management 
option used on these aforementioned outcome measures. 
Thus, the more cost-effective management option may 
be identified for a particular condition. Miyazaki et al, for 
example, conducted a prospective cohort study model of 
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47 patients with spinal metastasis who had a surgical indi-
cation from 2010 to 2014.34 This cohort was divided into 
a group of 31 patients who underwent spinal surgery and 
another group of 16 patients who did not. Therefore, this 
study assessed the cost-effectiveness of surgical treatment 
compared to non-surgical management in patients with 
spinal metastasis.
Computer-simulation models allow the evaluation of 
the effect of a proposed management option used for 
patients without the need for a real-life clinical study. 
These models should use the most rigorous and up-to-
date information for clinical parameters from the literature. 
The European Network for Health Technology Assessment 
recommends that if computer modelling is used, it should 
always be justified and it is imperative that it is presented 
with transparency so that it may be reproduced.26
The three most frequently used types are discussed 
below.
Decision trees
Decision trees offer a diagrammatic illustration of a deci-
sion problem regarding which management option to 
use out of multiple possibilities, as faced by clinicians for 
a particular condition. They are the simplest of the com-
monly used decision modelling techniques. They are used 
to model problems that involve a series of choices which 
are in turn constrained by previous decisions. They con-
sist of two key components: branches and nodes. Nodes 
represent the key elements of a decision problem in a 
computer model and the branches stemming from them 
represent their possible outcomes.35
Nodes are divided into three types: decision nodes, 
probability nodes and terminal nodes. Decision nodes 
represent a possible decision that can be made by the cli-
nician (e.g. which management option to use). Depend-
ing on the decision made, the patient’s health state moves 
along one or more branches. Probability nodes represent 
probability-based events that follow a decision node or 
another probability node. For example, at these nodes, 
the disease may develop a certain complication with a 
given probability or progress without it. Terminal nodes 
represent the final outcome of a decision analysis that fol-
lows a certain combination of decisions and probability-
based events. These outcomes include: cured, death, or 
a health state somewhere in between.36 The branches 
extending out from these nodes are mutually exclusive 
and collectively exhaustive (must add up to one). In addi-
tion, for a certain final outcome, by multiplying along the 
nodes and branches taken to reach it, one may find the 
overall probability for it to occur following a clinical deci-
sion or a series of decisions. The health outcome meas-
ures of interest (e.g. health utilities) are attached to the 
distinct final outcomes of the tree. Costs may be attached 
to both events within the tree and to the final outcomes. 
Therefore, for a particular pathway that follows a certain 
decision on which management option to use, the sum-
mation of the component costs involved until the final 
outcome is reached as a result of that pathway gives 
the respective total costs involved.37 Zindel et al used a 
decision tree model to illustrate the decision problem of 
choosing rivaroxaban or enoxaparin sodium for thrombo-
prophylaxis after total hip and knee replacement in the 
German healthcare setting.38
However, decision trees (see Figure 1) can become very 
complex when used to model chronic disease because this 
will inevitably involve many lengthy pathways represent-
ing recurring events. This is very time-consuming both to 
interpret and analyse
Markov models
Markov models are the most common type of model 
used in economic evaluations of healthcare management 
options. These models assume the patient is always in 
one of a finite number of discrete ‘Markov’ states. Within 
a Markov model, events are modelled as transitions from 
one health state to another one. The time horizon used 
for the model is split into clinically meaningful time inter-
vals, or ‘cycles’, of equal length. At the end of each cycle, 
a patient may either remain in the same health state or 
move to a consequent one. These transitions between 
health states continue until a patient enters an absorbing 
state. This refers to a state where, once entered, it can-
not be left (e.g. death). The occurrence of these of events 
is dictated by conditional probabilities. These probabili-
ties, as with decision trees, are conditional upon the last 
health state the patient was in. However, it is important 
to acknowledge that transition probabilities may change 
with time.37
For each of the health states modelled, health utility 
values can be attached which reflect the quality of life for 
the state. Likewise, costs are also attached to each health 
state reflecting the costs incurred of remaining in that 
particular state for the duration of one cycle. To calculate 
the QALYs for each patient for particular management 
options, the health utilities associated with each health 
state the patient experiences are multiplied by the associ-
ated time spent in them. These values are then summed 
across all health states experienced in the model. Simi-
larly, the total costs involved for particular management 
options are calculated for each patient by multiplying the 
costs incurred by each health state the patient experiences 
by the time the patient spends in that state. These costs 
are then summed across all the experienced health states 
in the model.37
Markov models (see Figure 2) are used when there are 
many potential health states with the possibility of bidirec-
tional transition between them. This usually applies to the 
modelling of chronic disease. As mentioned previously, 
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decision trees will become far too complex to model such 
problems efficiently.
Health model microsimulations
Health model microsimulations are very detailed analy-
ses that use highly realistic computer-simulated individu-
als that differ in various characteristics.40 These include 
factors such as age, gender, ethnicity and educational 
attainment. The populations used are to reflect that of the 
desired country of study and so are the most difficult to 
create. For example, Si et al used a microsimulation model 
for the cost-utility evaluations of various pharmaceutical 
and primary care management options to treat osteopo-
rosis in the Australian population.41 These studies evalu-
ate the effect of the particular management option on the 
entire population of interest. The model tracks individuals 
throughout their lifetime to see whether or how long the 
disease persists, what happens to it and the medical costs 
incurred throughout this time period.
These models are particularly useful when individuals 
have a mixture of interrelated (and often dynamic) risk fac-
tors that influence the experience of disease over time. This 
is because the model cycles throughout the lifespan of each 
individual one by one, twice, with aggregation occurring 
at the end. The first cycle just includes the base case. The 
second cycle includes the base case with the management 
option. Following this, the two cycles are compared to show 
the impact of each management option on health out-
comes and differences in costs. These simulations are very 
similar to randomized controlled trials. However, microsim-
ulations allow the understanding of the effects and costs of 
a particular management option over a much longer time 
horizon than a real-life study with regard to future costs, 









































Fig. 2 An example of a Markov model.
Source: Adapted from Pennington et al, who used a Markov model to 
compare the cost-utility of five commonly used cemented brands of 
unconstrained prostheses with fixed bearings in total knee arthroplasty.39
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Sensitivity analysis
A sensitivity analysis can be used to assess the level of con-
fidence that a researcher may have in the conclusions of 
a CUA study. Within these studies, uncertainty may derive 
from the parameter values (e.g. due to sampling bias), 
assumptions made for unknown or parameter values 
within a given range, or the structure of the model itself. 
The objective of the sensitivity analysis is to appreciate 
uncertainty inherent in the study and allows the estima-
tion of a confidence interval for the ICUR reported.
There are various sensitivity analysis methods. They all 
function by varying the parameter values used for which 
substantial uncertainty exists and then recording the 
results of the economic evaluation to see how they are 
affected. If the results change significantly in response, 
then these variables are likely to heavily influence the 
result of the economic evaluation. These potential sources 
of uncertainty may include the associated costs of the 
management option, the complication rates, and the 
quality-of-life estimates considered. Such values need to 
be stringently varied across a range of clinically plausible 
values to test the fidelity of the original results of the CUA 
where mean values were used. This allows the reviewer to 
determine which of these parameters are the key drivers 
of the results of the CUA and so they are very informa-
tive.42 To meet the preferences of most EU countries, 
the EUnetHTA guidelines recommend performing both 
deterministic (one-way, multi-way and threshold) and 
probabilistic sensitivity analysis.26 The different types of 
sensitivity analysis are discussed below.
One-way analysis
In deterministic one-way sensitivity analysis, the uncertain 
input parameters are varied one by one by setting each to 
its upper and lower bounds. The impact of these changes 
in one parameter on the main outcomes of the primary 
analysis is then assessed with all other parameter values 
set at their mean values. This analysis gives an indication 
of the impact of individual parameter uncertainty on the 
main outcome measures. As a result of this input varia-
tion, the ICUR may increase, decrease or remain essen-
tially the same.
Multi-way analysis
Deterministic multi-way analysis is very similar in princi-
ple to one-way analysis except that multiple parameters 
are varied simultaneously, and the outputs of the analysis 
are then measured. For example, Brauer et al used both 
one-way and multi-way sensitivity analysis in a cost-utility 
analysis of operative versus non-operative management 
of displaced intra-articular calcaneal fractures.42 Both 
revealed that the cost per additional QALY gained with 
operative management over non-operative management 
was sensitive to the inclusion of estimates of costs due to 
time lost from work.
Threshold analysis
Deterministic threshold analysis attempts to identify the 
value of a given parameter where the output of the anal-
ysis changes sign regarding whether or not a particular 
management option is of a greater cost-utility compared 
to a comparator. The parameter is varied until this tipping-
point is found for it with the remaining inputs kept at their 
mean values. Parameters that have tipping-points closer 
to their mean value indicate that they hold a strong influ-
ence over the outcome of the model.
Probabilistic analysis
In most computer-simulation models, each of the uncer-
tain parameters (such as the health state transition proba-
bilities) are assigned point estimate values. These are often 
based on meta-analysis data. Thus, they will inevitably 
have a range of possible values around them. For exam-
ple, if the 95% confidence interval of a particular probabil-
ity value (e.g. the probability for a management option to 
be successful) published in a meta-analysis is within a very 
close range, then greater certainty is indicated.43
In probabilistic sensitivity analysis, instead of assign-
ing a single value to each parameter, computer software 
is used to assign a distribution to all parameters in the 
model, which reflects the uncertainty in the true value. All 
parameters must remain practical (e.g. probabilities must 
remain between zero and one and costs cannot be nega-
tive). From each distribution, samples are then repeatedly 
drawn and are used as model inputs. Each unique com-
bination of inputs (a single ‘simulation vector’) results in 
a unique combination of model outputs. As a result, by 
considering the results of many simulations, an estimation 
of the expected (mean) model outputs and the uncer-
tainty associated around them may be derived.44
Ponnusamy et al conducted a Markov study to assess 
the cost-utility of TKA against non-operative management 
in patients across six body mass index (BMI) cohorts. A 
probabilistic analysis was performed with an ICER of 
$30,000/QALY which revealed that TKA would be cost-
effective in 100% of simulations of patients with a BMI 
below 50 and in 99.16% of simulations of super-obese 
(BMI of 50 and over) patients.45
Grading the quality of CUA studies
Many CUA studies are produced using vastly different 
methodologies, reporting and data sources. Therefore, it is 
important for an objective grading system to exist to assess 
the quality of each of these studies with proven high con-
struct and content validity. These assessment instruments 
will assist the identification of CUA studies of superior merit. 
312
Table 2. The main sources of limitations associated with CUA studies (adapted from the European Network for Health Technology Assessment)49
Source of limitation Description
Efficacy/effectiveness and 
safety of the management 
option
 • All evidence should be taken into account, both published and unpublished, to avoid publication and reporting bias of these 
metrics.
 • A balanced assessment of all clinical evidence must be performed as this provides the input for the economic evaluation.
 • The impact of adverse events on costs and health outcomes should be taken into account.
Comparator  • Ideally, the comparator should be the reference treatment according to the most up-to-date high-quality clinical practice 
guidelines at European or international level with strong literature evidence on efficacy and safety, and with recognized 
regulatory approval for the respective clinical indication.
 • Therefore, readers must be aware of the inclusion of inappropriate, non-cost-effective comparators in place of more relevant 
(and possibly more cost-effective) ones to calculate the ICER values.
Subgroup analysis  • Measurements of cost-effectiveness for an overall study population may lead to incorrect management option 
recommendations as cost-effectiveness may differ between subgroups.
 • For example, the absolute treatment efficacy of a particular management option may differ based on sociodemographic (e.g. 
age, sex, socioeconomic class etc.) or clinical (e.g. baseline risk, disease severity etc.) characteristics.
 • Often, subgroup analyses are simply exploratory and should be interpreted with caution as the subgroup sizes are often too 
small to detect moderate differences.
Baseline risk of the target 
population
 • There may be differences in the baseline risk for certain events in a specific population (e.g. that selected for an RCT) versus 
the general population to which the decisions of policy-makers apply.
 • A failure to adjust for these differences may have a significant impact on the modelled absolute health outcomes and costs.
Compliance  • In most cost-effectiveness evaluations, compliance to the particular management option is not explicitly considered but is 
likely to have an impact on cost-effectiveness.
 • If compliance is not the same in the underlying trial population compared to the target population, then the health outcomes 
and costs may be biased.
 • Ideally, the impact of poor adherence and the overall adherence in both study populations should be quantified using the 
appropriate evidence.
Quality of life  • Readers should be cautious when non-evidence-based utility weights (e.g. based on expert opinion) are used because a 
generic utility instrument was not used in the underlying trials.
 • If different direct or indirect methods were used to evaluate the health utilities of the management options under comparison, 
there is increased uncertainty as different values may be achieved with each.
In addition, a greater standard of reporting will inevitably 
be encouraged, leading to greater quality and rigour. Four 
commonly used instruments are discussed below.
The Quality of Health Economic Studies (QHES) instru-
ment is one such method. The QHES highlights the impor-
tance of suitable methods, valid, transparent results and 
their comprehensive reporting in each CUA study. There 
are 16 independent criteria used, with each having a 
weighted point value. The more important criteria are 
considered to be of greater relative weight. The perfect 
quality score for a study is 100, which is calculated by the 
sum of all the points of all the questions answered ‘yes’.46
The Consensus Health Economic Criteria (CHEC) check-
list focuses only on the methodological quality of economic 
evaluations. It is only suitable for systematic reviews based 
on full economic evaluations based on clinical trials (cohort 
studies, randomized controlled trials and case-control 
studies) that compare costs and health outcomes of two or 
more alternative options (e.g. management options). Both 
costs and health outcomes of each of the alternatives must 
be examined. The CHEC cannot be used for model-based 
study designs due to other methodological criteria being 
relevant which are absent in this checklist. The checklist 
consists of 19 binary yes-or-no questions. Each question 
pertains to a single category. A, ‘no’, response should be 
given if insufficient information was available in the article 
or in other relevant published material.27
The Consolidated Health Economic Evaluation Repor-
ting Standards (CHEERS) checklist was developed to 
facilitate consistent and transparent reporting of eco-
nomic evaluation research. Importantly, it reflects the 
most up-to-date and widely accepted standards in this 
field. It was initially designed as a guide to best prac-
tice reporting for such research types. However, several 
researchers have used it as an appraisal tool for risk of bias 
in these studies, but it should be acknowledged that it is 
not intended to assess methodological quality. It consists 
of a 24-item checklist with accompanying recommenda-
tions on the minimum amount of information required 
when reporting such economic evaluations.47
It should be noted, that although these instruments 
were developed to promote a greater standard of report-
ing in economic evaluations over time, this has not always 
been observed within orthopaedics. For example, as dem-
onstrated by Rajan et al, there has been a growing number 
of lower-quality orthopaedic-based CUA studies (assessed 
using the QHES) relating to the management options of 
the upper limb in recent years.48
Common limitations in cost-utility analysis 
studies
Although CUA studies offer valuable information for 
healthcare decision-makers, they are vulnerable to a vari-
ety of potential limitations that may harm their overall 
credibility. The main limitations, as outlined by the Euro-
pean Network for Health Technology Assessment, are 
described in Table 2.49
(continued)
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Concluding remarks
In summary, cost-utility analysis studies are becoming 
increasingly important within trauma and orthopaedic 
surgery. They offer a powerful tool to elucidate valuable 
information that will help inform clinical decision-making 
which will ultimately lead to the optimization of routine 
clinical practice via the incorporation of the most cost-
effective methods. This review has outlined the main con-
cepts required to understand the cost-utility literature and 
provides a basic framework for their future conduct.
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Time horizon and 
extrapolation
 • As a modelled time horizon increases and/or there is more extrapolation, there is a greater associated inherent uncertainty.
 • When extrapolating data beyond the duration of the clinical trial, it is important for the underlying assumptions and data 
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 • The impact of different extrapolation scenarios should be assessed via sensitivity analysis to adequately capture the 
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Context-specific costs  • Ideally, prices and resource used for specific cost items should be summarized in a prices * quantities table to provide 
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gathering cost information as it may be different from other countries.
 • Patient costs are often skewed towards those carrying lower costs. The assumed parametric statistical distributions of 
common applied statistical tests may not reflect this and so leading to incorrect confidence intervals and p-values.
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the best available evidence, be plausible and adequately reflect uncertainty.
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 • It is important to consider the transferability of study findings from an economic evaluation performed in one specific 
decision-making context to another.
 • There are now checklists that help investigators to identify the parameters that are more vulnerable to differ between settings 
which may have implications for the ICER values and so cost-effectiveness.
ICER threshold  • Authors may potentially use WTP thresholds that are relatively high and are not accepted in their country at that given time. 
Therefore, it is crucial to justify the reasons for the specific WTP chosen.
 • Conclusions about cost-effectiveness in countries where there is no explicit WTP cannot be made as they may lead to 
incorrect conclusions.
Publication bias of 
economic evaluations 
and conflicts of interest
 • Industry-sponsored cost-effectiveness studies are more likely to report favourable conclusions than those with other funding 
sources, which may imply a source of publication bias.50
 • There may be a tendency for favourable input variables to be chosen for the sponsor’s product.
Notes. CUA, cost-utility analysis; ICER, incremental cost-effectiveness ratio; RCT, randomized controlled trial; WTP, willingness-to-pay.
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